Regular Article
The HMG-CoA Reductase Inhibitor Pravastatin Stimulates Insulin Secretion through Organic Anion Transporter Polypeptides

https://doi.org/10.2133/dmpk.25.274Get rights and content

Summary:

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin has been reported to have a beneficial effect on reducing the new onset of diabetes as well as lowering plasma lipids. Because pravastatin is a water-soluble organic anion, it cannot easily penetrate the lipid bilayer of the cell membrane. As the precise mechanisms of the effect of pravastatin on glucose metabolism and diabetes have not been clarified, we examined the roles of the organic anion transporter family on pravastatin-treated islet and adipocyte functions. Rat oatp1/slco1a1, oatp2/slco1a4 and oatp3/slco1a5 were expressed in the pancreas, and rat oatp3/slco1a5 was also detected in rat insulinoma cell line INS-1e. Pravastatin was transported not only by oatp1/slco1a1 and oatp2/slco1a4, but also by rat oatp3/slco1a5. Pravastatin uptake into INS-1e cells was detected and this transport was inhibited by sulfobromophthalein and rifampicin, both of which are known to inhibit oatp family-mediated uptake. In addition, pravastatin enhanced the glucose-stimulated insulin secretion from INS-1e cells. When fat-loaded db/db mice were treated with pravastatin, glucose intolerance and insulin resistance were prevented. In addition, insulin secretion from isolated islets was enhanced by pravastatin. These data suggest that pravastatin has pleiotropic effects on islets through membrane transport under high fat/glucose conditions.

References (31)

  • A.K. van Vliet et al.

    Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types

    Biochim. Biophys. Acta

    (1995)
  • F. Guclu et al.

    Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome

    Biomed. Pharmacother.

    (2004)
  • T. Takagi et al.

    Effect of pravastatin on the development of diabetes and adiponectin production

    Atherosclerosis

    (2008)
  • J. Shepherd et al.

    Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

    N. Engl. J. Med.

    (1995)
  • D.J. Freeman et al.

    Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

    Circulation

    (2001)
  • Cited by (20)

    • Bioconversion of mevastatin to pravastatin by various microorganisms and its applications – A review

      2018, Biocatalysis and Agricultural Biotechnology
      Citation Excerpt :

      Clinically, pravastatin administration also increased adiponectin levels and reduced urinary protein excretion (Sakamoto et al., 2006). The serum glucose level during oral glucose tolerance test (OGTT) was significantly decreased by pravastatin treatment the improvement of OGTT results by pravastatin is attributed to the protective effect on insulin secretion of high-fat/glucose-loaded β-cells, in addition to improving insulin tolerance (Abe et al., 2010). It is less myotoxic than lovastatin and simvastatin, which may be related to its relatively poor uptake by muscle cells (Masters et al., 1995).

    • Modulation of adiponectin as a potential therapeutic strategy

      2014, Atherosclerosis
      Citation Excerpt :

      For example, pravastatin increased circulating adiponectin levels in humans, whereas simvastatin did not [5]. Another study showed that pravastatin enhanced the glucose-stimulated insulin secretion from INS-1 cells and improved glucose intolerance and insulin resistance in fat-loaded db/db mice [60]. In contrast, some statins (particularly at high doses) caused unfavorable pleiotropic effects, including reduced insulin secretion and exacerbation of insulin resistance [61].

    • Therapy for CKD and DKD

      2023, Folia Pharmacologica Japonica
    View all citing articles on Scopus
    View full text